BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT00362726
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT00362466
- Locations
- 🇺🇸
Santee Hematology/Oncology, Sumter, South Carolina, United States
🇺🇸M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸Local Institution, Houston, Texas, United States
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT00362713
- Locations
- 🇺🇸
The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Vinflunine in Patients With Gastric Cancer
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT00359476
- Locations
- 🇵🇭
Local Institution, Quezon City, Philippines
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 186
- Registration Number
- NCT00359450
- Locations
- 🇬🇧
Local Institution, Oxford, Oxfordshire, United Kingdom
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Phase 2
Withdrawn
- Conditions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00357461
Drug Interaction Study With Proton Pump Inhibitor
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT00357240
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00357188
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Atazanavir Twice Daily
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT00357721
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00357604
- Locations
- 🇺🇸
Covance Cpu, Inc, San Diego, California, United States
© Copyright 2024. All Rights Reserved by MedPath